Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage

By S. Mayer. Stroke, 2007

1,061 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Inflammation after Intracerebral Hemorrhage (2007, background): “In the near future, additional strategies that target inflammation in the very early phase of hemostasis (Mayer et al, 2005) could offer exciting new promise in the therapeutic approach to ICH.”
Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. (2006, background): “No arterial thromboembolic AEs were found in the placebo group and thrombotic events increased with increasing rFVIIa dose.(13) The primary end point in this phase 2 dose-ranging trial was not mortality or disability, but the combined rFVIIa groups had lower mortality without an increase in severe d”